Boston Scientific announces results for third quarter 2026
Boston Scientific reported Q3 2026 net sales of $5.138B, up 1.5% YoY. GAAP EPS was $0.40, down from $0.51 YoY, while adjusted EPS was $0.73, slightly down from $0.75. The company faced challenges, including a cybersecurity incident, but remains confident in its long-term strategy. It announced clinical trial enrollment, FDA clearances, and a collaboration with Heartflow. Full-year net sales growth is now estimated at 4.25% reported and 3.75% organic, with adjusted EPS guidance of $3.16-$3.18.
How this was made
The 30-second read
Why it matters
The mixed results—steady Q3 sales but a projected Q4 decline—create a near‑term bearish bias, while new product approvals could be a catalyst later.
Market read
First‑report earnings and guidance for a mid‑cap med‑tech firm; likely influences BSX and peers in the sector.
What to watch
The new FDA clearances and clinical trial enrollment may offset short‑term sales concerns.
Background
Boston Scientific's Q3 earnings press release provides detailed segment performance, new product clearances, and updated full‑year guidance.
Ticker impact
Boston Scientific disclosed Q3 2026 results and full-year guidance, including lower Q4 sales outlook.
likely downside as investors price in weaker Q4 outlook
The new guidance is below consensus expectations, and the Q4 sales decline signals slower momentum.
Market effects
Medical device sector may see modest pressure as a large player signals slower growth.
U.S. healthcare stocks could see slight pullback in the afternoon session.
Limited to investors tracking U.S. med‑tech equities; no broader macro effect.
Counterpoint
If the guidance reflects a strategic pivot rather than weakness, the stock could rebound on long‑term growth prospects.
Key entities
- companyBoston Scientific
Medical device manufacturer reporting Q3 2026 results.
- companyHeartflow, Inc.
Partner in AI‑powered PCI planning collaboration.
